Recon: Moderna Begins Recruitment for Coronavirus Vaccine Study; Europe Braces for Coronavirus-Related Drug Shortages

• House passes $8.3 billion bill to battle coronavirus; Senate vote due Thursday (Reuters) (NYTimes)
• McConnell Provides Update on Supplemental Funding to Combat the Coronavirus (McConnell)
• What’s in the coronavirus funding package? (Politico)
• Recruitment Begins for First Test of Experimental Coronavirus Vaccine (WSJ)
• Fragile safety net leaves US economy vulnerable to coronavirus hit (Reuters)
• Trump falsely claimed that Obama administration slowed down diagnostic testing (CNN)
• Quest Diagnostics to launch coronavirus test service (Reuters) (Press)
• Big Pharma is on a stock buyback spree (Axios)
• NeuroMetrix settles $4m false advertising case with FTC (MassDevice) (FTC)
• Sanofi, Fighting Back in Insulin Price Debate, Says Its Net Prices Fell 11% (WSJ) (Endpoints)
• Pfizer, Amgen, Lilly spent most to lobby Congress, study finds (BioPharmaDive)
• Prosthetic innovation: 'It's like you have a hand again' – study (Reuters)
• What to expect at health tech’s big HIMSS conference — if it happens (STAT)

• Europe could face more drug shortages as coronavirus squeezes supplies (Reuters)
• China announces wider health system reforms amid coronavirus outbreak (Reuters)
• Anges to develop coronavirus vaccine with Osaka University (Reuters)
• Coronavirus Epidemic Draws Scrutiny to Labs Handling Deadly Pathogens (WSJ)
• Oh, Canada! Vertex battles another country over access to cystic fibrosis treatments (STAT)
• GSK's Emma Walmsley awarded £8.4M pay package after £2.5M rise, finally catching up with fellow pharma CEOs (Endpoints)
• Zydus Cadila gets DCGI nod for world's first drug to treat liver disease (Economic Times)
• New TB drug regimen controls resistant disease in 9 of 10 cases: study (Reuters) (NEJM)

• Coronavirus and the $2bn race to find a vaccine (Financial Times)
• The coronavirus test will be covered by Medicaid, Medicare and private insurance, Pence says (CNBC)
• Scientists were close to a coronavirus vaccine years ago. Then the money dried up. (NBC)
• EU grants governments fiscal leeway to fight coronavirus impact, eyes more (Reuters)
• FDA Working With Four Labs To Deploy COVID-19 Diagnostic Tests (IHP-$)
• Co-Diagnostics says demand for coronavirus test kits surge, shares soar (Reuters)
• EliTech Gets CE Mark for SARS-CoV-2 Detection Kit (GenomeWeb)
• Coronavirus task force rolls out guidelines for nursing homes (NBC)
• Senate Homeland Security Ranking Member Calls on Pence to Launch Central Coronavirus Website (Letter)
• HHS clarifies US has about 1% of face masks needed for ‘full-blown’ coronavirus pandemic (CNBC)
• Some VA Stockpiles of Protective Medical Masks Aren’t Usable (Bloomberg)
• Coronavirus spending: an expense — or an investment? (STAT)
• California declares emergency over coronavirus as death toll rises in US (Reuters)
• How blood plasma from recovered patients could help treat the new coronavirus (STAT)
• Robotic arm designed in China could help save lives on medical frontline (Reuters)
• From ferrets to mice and marmosets, labs scramble to find right animals for coronavirus studies (STAT)
• A Chinese Doctor Injected Herself With an Untested Coronavirus Vaccine (Vice)
• China coronavirus infections spike in central city of Wuhan (Reuters)
• Italy may raise coronavirus support spending to 5 billion euros, minister says (Reuters)
• Coronavirus death toll jumps to 107 in Italy, all schools shut (Reuters)
• Iran reports 107 deaths, 3513 infections from coronavirus: health ministry spokesman (Reuters)
• South Korea declares new 'special care zone' as coronavirus spreads (Reuters)
• Coronavirus infections jump to 82 in the Netherlands: RIVM (Reuters)
• New York confirms two more coronavirus cases, state total at 13 (Reuters)
• France reports two more coronavirus deaths, taking total to six (Reuters)
• France says it now has 285 confirmed cases of coronavirus (Reuters)
• Hungary confirms first two coronavirus cases (Reuters)
• Ireland confirms four new COVID-19 cases to bring total to six (Reuters)
• Egypt registers first coronavirus case in an Egyptian national returning from Europe (Reuters)
• Algeria reports nine new coronavirus cases: health ministry (Reuters)
• Iraq reports second coronavirus death in Baghdad (Reuters)
• As India coronavirus cases spike, experts daunted by prospect of South Asia spread (Reuters)
• India shuts Delhi schools, imposes new travel restrictions over coronavirus (Reuters)
• Japan plans to order two-week quarantine for all Chinese, South Korean visitors – Yomiuri (Reuters)
• Thailand reports four new coronavirus cases, total 47 (Reuters)
• Slovenia confirms first case of coronavirus: health minister (Reuters)
• Hong Kong quarantines dog for coronavirus, experts caution over pet spread (Reuters)
• Coronavirus: Cruise Ship In Limbo Off California After Former Passenger Died (NPR)
• Chinese President Xi's Japan visit delayed due to coronavirus (Reuters)

• Is it time to nationalise the pharmaceutical industry? (BMJ)
• 'Dramatic times': How did an $8B surge in NIH grants over five years change research on the ground (if at all)? (Endpoints)
• Changing Drug Market Dynamics: An Interview with Craig Garthwaite (The Incidental Economist)
• Novartis taps Orionis to pursue 'historically elusive targets' (Fierce)
• Nobody but Deerfield wants Melinta; Novartis finds a new drug discovery partner (Endpoints)
• Core (Values) Workout (LifeSciVC)
• MacroGenics loses CMO Jon Wigginton as commercialization looms (Endpoints)
• Servier bags expanded rights to Cellectis' CD19 CAR-Ts (Fierce)
• After a trendsetting role in global biotech venture investing, David Mott parts ways with NEA (Endpoints)
• PsiOxus lures Lillie from Merck to fill CMO position (Fierce)
• Insights into how Novo Nordisk's Saxenda cuts food cravings may inspire new obesity drugs (Fierce)
• How do depressed rats respond to psychedelics? New data offer insight into the human experience (Endpoints)
• Hikma halts production of pain drug because of 'gelatinous particles' in vials (Fierce)
• Q&A: Mike Dixon (PMLive)
• Best Practices in Drug and Biological Product Postmarket Safety Surveillance for Food and Drug Administration Staff; Draft Document; Reopening of Comment Period (FDA)
• Training Program for Regulatory Project Managers; Information Available to Industry (FDA)

• FDA Accepts Mylan’s Bevacizumab Biosimilar Application (Big Molecule Watch)
• Urovant Sciences Announces U.S. FDA Acceptance of New Drug Application for Vibegron for the Treatment of Overactive Bladder (Press)
• Can-Fite Updates on Clinical Milestone for its Phase III Rheumatoid Arthritis Study with Piclidenoson; Drugs Combating Rheumatoid Arthritis are Currently Introduced for the Treatment of the Coronavirus (Press)
• PsiOxus Therapeutics Announces Clinical Trial with Third Cancer Gene Therapy Treatment and Appointment of New Chief Medical Officer (Press)

• Axonics execs bullish on breaking Medtronic market stranglehold (MedtechDive)
• Former FDA leader joins medical device security startup (Health IT & CIO Report)
• Exact Sciences closes takeovers of 2 cancer testing businesses (MedtechDive)
• Boston Scientific settles Canadian pelvic mesh case for $21.5m (MassDevice)
• Could Altair Medical’s wearable reduce opioid deaths? (MassDevice)
• Aerin Medical Announces FDA Clearance and U.S. Launch of Innovative Nonsurgical Procedure for Chronic Rhinitis (Press)
• Biogennix Receives FDA Clearance for Expanded Use of Agilon Moldable Bone Grafting Solution in Spine Procedures (Press)
• Reflow Medical Announces 510(k) Clearance for an Expanded Indication for the Wingman Catheter to Cross Chronic Total Occlusions (CTOs) in Peripheral Artery Disease (Press)

• Schneider, Hice, Schakowsky Introduce Bipartisan Bill To Address Medical Device Shortages (Press)
• Federal Circuit Hears Argument Regarding the Denial of Genentech’s Motion to Preliminarily Enjoin Amgen’s Sales of Trastuzumab (Big Molecule Watch)
• Amgen Responds to Hospira’s Motion For Rehearing En Banc of the Safe Harbor Ruling in the Epoetin Biosimilar Dispute (Big Molecule Watch)
• Loeb & Loeb Picks Up DLA Piper FDA Team Head In DC (Law360-$)
• Vaccine IP Under Microscope With Coronavirus Outbreak (Law360-$)
• 9th Circ. Says Judge Wrongly Put Warning In FDA Complaint (Law360-$)
• Gilead Can't Duck Sweeping Competition Suit Over HIV Drugs (Law360-$)
• Celgene Tells Justices Retroactive IPRs Are Unconstitutional (Law360-$)
• Always Liability Increases? – Don’t Mess With Texas! (Drug & Device Law)
• USDA Announces Delay of Enforcement of Requirement for DEA Registration of Hemp Testing Laboratories (FDA Law Blog)
• Life Sciences Court Report (Patent Docs)

• FDA Advisory Committee Calendar
• Advancing Animal Models for Antibacterial Drug Development – 5 March 2020

• EU Committee Gets Tough On Environmental Pharma Pollution (Pink Sheet-$)
• UK looks to use Brexit to make device industry more transparent (MedtechDive)
• Stada Arz now biggest foreign pharma investor in Russia (PharmaLetter-$)
• ‘Last Chance To Save European Innovation' (Pink Sheet-$)
• Alnylam Pursues Value Framework To Accelerate Givlaari Access In EU (Scrip-$)
• Janssen files for EMA approval of ponesimod in multiple sclerosis (PharmaLetter-$)
• Illegal imports of medicinal products: simplified procedure proves its worth (Swissmedic)

• Special Report: Before coronavirus, China bungled swine epidemic with secrecy (Reuters)

• Industry seeks exemption for drugs manufactured for only export purposes from export restrictions (Pharmabiz)

• International work-sharing initiative - Baloxavir marboxil (Xofluza) (TGA)